Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
South Korean Won Leads Asian FX Losses as Dollar Rises 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Trump Weighs Capital Gains Tax Cuts Ahead of Midterms 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
ADNOC Gas Targets Up to $4B Profit in 2026 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
